Drugs / ANZ-521
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00800007 Comparator | Nov 2008 → Feb 2009 | chronic hepatitis C virus infection | Anza Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANZ-521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00800007 ↗ |
| Route | Intravenous | “multiple intravenous doses of ANZ-521” NCT00800007 ↗ |